Jianlin Pharmaceutical key facts
- Manufacturer of pharmaceutical formulations intended to develop critical medicines for respiratory, cerebrovascular, anesthesia, and emergency care.
- Notable investors include Chengdu Longchu Equity Investment Fund Management.
- Status: Privately Held (backing).
Who backs Jianlin Pharmaceutical
1- ·Watch Jianlin Pharmaceutical: the Monday email on marks, rounds and moves
Jianlin Pharmaceutical funding rounds
No funding rounds for Jianlin Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Jianlin Pharmaceutical investors
1 investor is on record for Jianlin Pharmaceutical, including Chengdu Longchu Equity Investment Fund Management.
About Jianlin Pharmaceutical
Manufacturer of pharmaceutical formulations intended to develop critical medicines for respiratory, cerebrovascular, anesthesia, and emergency care. The company offers inhalation solutions, nasal spray systems, dry powder inhalers, and injectable formulations, thereby enabling them to improve treatment precision, enhance patient safety, and accelerate therapeutic outcomes.
- Sector
- Healthcare
- HQ
- Chengdu, China
- Founded
- 2022
- Website
- jianlinpharma.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Jianlin Pharmaceutical doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.